Qualitest Pharmaceuticals, the sixth largest generics company in the US as measured by prescriptions filled, is being acquired by Endo Pharmaceuticals in a cash deal worth US$1.2 B. In buying Qualitest, Endo aims to provide critical mass to its generics business and boost its portfolio of pain management products.